AOD-9604: What the Actual Fat-Loss Evidence Shows vs. the Marketing Claims

AOD-9604 is often marketed as a fat-burning peptide derived from growth hormone, engineered to isolate the fat-metabolizing effect of GH without its growth-promoting or blood-sugar-affecting properties. The actual clinical trial history behind that claim is worth knowing before treating it as established.

What AOD-9604 Actually Is

AOD-9604 is a synthetic fragment corresponding to amino acids 176-191 of the human growth hormone molecule — specifically the region researchers identified as responsible for GH's lipolytic (fat-mobilizing) effect, separate from the region responsible for GH's effects on growth and insulin resistance. The scientific premise, isolating one functional piece of a larger hormone, is a legitimate area of peptide research, and this specific fragment was studied with real pharmaceutical development resources behind it, not just informal use.

The Clinical Trial History

AOD-9604 went through actual Phase II clinical trials for obesity, sponsored by a pharmaceutical company (Metabolic Pharmaceuticals), specifically because the fat-mobilizing fragment hypothesis was considered promising enough to pursue formal drug development. The trials, however, did not show weight-loss results significant enough to justify continued development toward approval — the sponsoring company halted further development of AOD-9604 as an obesity treatment following underwhelming Phase II results, and it was never submitted for or granted FDA approval for weight loss or any other indication.

Why the Marketing Persists Anyway

The compound's mechanistic story — a piece of growth hormone isolated for its fat-burning region — is scientifically coherent enough to sound credible, and animal studies did show some lipolytic activity, which is likely what sustains its marketing in the research-chemical and compounding space today. But animal-model lipolytic activity and a mechanistically plausible story are a different evidence tier than a successful human clinical trial program, and the human trial data that did exist showed the effect wasn't strong enough to support the fat-loss claims made about it.

Regulatory and Sourcing Status

Because it never gained approval, AOD-9604 sold today is almost exclusively a research-chemical product, not a compounded pharmacy or approved drug — carrying the same sourcing and quality-verification concerns that apply broadly to that category, on top of the underwhelming efficacy signal from its own trial history.

Practical Takeaway

AOD-9604's fat-burning fragment concept was taken seriously enough to reach actual Phase II human trials — but those trials didn't produce evidence strong enough to support the claims still made about it in marketing, and development for obesity was discontinued as a result. That's a meaningfully different, weaker evidence position than compounds like tesamorelin that carry an actual approval behind their claims, and it's worth weighing that history against the more optimistic framing common in how AOD-9604 is sold today.